Literature DB >> 31481589

The Future of Nuclear Medicine as an Independent Specialty.

Johannes Czernin1, Ida Sonni2, Aria Razmaria2, Jeremie Calais2.   

Abstract

In this article, we provide an overview of established and emerging conventional nuclear medicine and PET imaging biomarkers, as the diagnostic nuclear medicine portfolio is rapidly expanding. Next, we review briefly nuclear theranostic approaches that have already entered or are about to enter clinical routine. Using some approximations and taking into account emerging applications, we also provide some simplified business forecasts for nuclear theranostics. We argue that an optimistic outlook by the nuclear medicine community is crucial to the growth of the specialty and emphasize the urgent need for training adaptations.
© 2019 by the Society of Nuclear Medicine and Molecular Imaging.

Keywords:  molecular imaging; nuclear medicine; theranostics

Mesh:

Substances:

Year:  2019        PMID: 31481589     DOI: 10.2967/jnumed.118.220558

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  10 in total

1.  Knowledge and perception of nuclear medicine by radiologists in French-speaking sub-Saharan Africa.

Authors:  Kokou Adambounou; Koffi Assogba Ahonyi; Gilles David Houndetoungan; Houndetoungan Ouedraogo; Bidamin Ntimon; Fabrice Sodogas; Lantam Sonhaye; Victor Adjenou
Journal:  Asia Ocean J Nucl Med Biol       Date:  2022

Review 2.  Radiotheranostics in oncology: current challenges and emerging opportunities.

Authors:  Lisa Bodei; Ken Herrmann; Heiko Schöder; Andrew M Scott; Jason S Lewis
Journal:  Nat Rev Clin Oncol       Date:  2022-06-20       Impact factor: 65.011

Review 3.  Molecular imaging in oncology: Current impact and future directions.

Authors:  Steven P Rowe; Martin G Pomper
Journal:  CA Cancer J Clin       Date:  2021-12-13       Impact factor: 286.130

Review 4.  Update on PET Tracer Development for Muscarinic Acetylcholine Receptors.

Authors:  Marius Ozenil; Jonas Aronow; Marlon Millard; Thierry Langer; Wolfgang Wadsak; Marcus Hacker; Verena Pichler
Journal:  Pharmaceuticals (Basel)       Date:  2021-06-02

5.  The integrated nuclear medicine and radiology residency program in the Netherlands: strengths and potential areas for improvement according to nuclear medicine physicians and radiologists.

Authors:  Ton Velleman; Thomas C Kwee; Rudi A J O Dierckx; Yfke P Ongena; Walter Noordzij
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-02-23       Impact factor: 10.057

6.  PSMA Expression Assessed by PET Imaging Is a Required Biomarker for Selecting Patients for Any PSMA-Targeted Therapy.

Authors:  Jeremie Calais; Johannes Czernin
Journal:  J Nucl Med       Date:  2021-11       Impact factor: 11.082

Review 7.  A review of the application of machine learning in molecular imaging.

Authors:  Lin Yin; Zhen Cao; Kun Wang; Jie Tian; Xing Yang; Jianhua Zhang
Journal:  Ann Transl Med       Date:  2021-05

8.  Joint EANM, SNMMI and IAEA enabling guide: how to set up a theranostics centre.

Authors:  Ken Herrmann; Luca Giovanella; Andrea Santos; Jonathan Gear; Pinar Ozgen Kiratli; Jens Kurth; Ana M Denis-Bacelar; Roland Hustinx; Marianne Patt; Richard L Wahl; Diana Paez; Francesco Giammarile; Hossein Jadvar; Neeta Pandit-Taskar; Munir Ghesani; Jolanta Kunikowska
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-04-11       Impact factor: 10.057

9.  Down-Regulation of Toll-Like Receptor 5 (TLR5) Increased VEGFR Expression in Triple Negative Breast Cancer (TNBC) Based on Radionuclide Imaging.

Authors:  Wen Jiang; Yeming Han; Ting Liang; Chao Zhang; Feng Gao; Guihua Hou
Journal:  Front Oncol       Date:  2021-07-15       Impact factor: 6.244

10.  Evaluation of [18F]tetrafluoroborate as a Potential PET Imaging Agent in a Sodium Iodide Symporter-Transfected Cell Line A549 and Endogenous NIS-Expressing Cell Lines MKN45 and K1.

Authors:  Mengda Niu; Jingjing Qin; Liang Wang; Yujia He; Chuanhuizi Tian; Yanyan Chen; Pufeng Huang; Zhiping Peng
Journal:  Mol Imaging       Date:  2022-02-27       Impact factor: 4.488

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.